Bicara Therapeutics Inc (NASDAQ:BCAX) at last check was buoying at $11.82 on current market day with a rise of 7.40% from its closing price on previous day.
Considering stock’s 52-week price range provides that BCAX hit a high price of $28.09 and saw its price falling to a low level of $7.80 during that period. Over a period of past 1-month, stock came subtracting -15.54% in its value.
With its current market valuation of $644.89 million, Bicara Therapeutics Inc is set to declare its quarterly results in July. Analysts are in estimates of -0.54 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -2.28 for current year with estimates of that growing to -2.43 in next year.
Digging deeper we become aware of the PEG ratio of the BCAX stock which is currently positioned at 0. It further provides that stock’s current price level is -4.83% away from its 20-day simple moving average and is -6.42% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 48.29 while volatility remained at 5.94% over the past week which changes to 13.57% when measuring it over the past month. Average true range or ATR is currently at 1.58. In predicting price targets of as low as $8 and as high as $48, analysts are in agreement on assigning the stock over the next 12 months average price target of $28. Stock’s current price level is 32.32% above from estimated low price target while it is -306.09% below the estimated high; and even if the BCAX’s share succeeded to reach the median price of $28, then the outlook of -136.89% could come to the excitement of the investors.
The percentage of outstanding shares held by the insiders is 39.92% while it is 62.30% for the institutional holders. Subtraction of -32.12% by stock’s current price to its year-to-date value in today’s trading is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.
